Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key Decisions in HIV Care: Considering the Use of Proviral DNA Genotyping to Inform ART Choice

Listen as John D. Baxter, MD, shares the latest data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience.
John D. Baxter, MD
Released: February 1, 2022

In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.

Listen as he gives his perspectives on:

  • US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotyping
  • US Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistance
  • Study 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistance
  • The BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistance
  • Between-class ART switches with underlying resistance
  • Susceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutations


Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity


John D. Baxter, MD

Professor of Medicine
Division of Infectious Diseases
Department of Pathology
Cooper Medical School of Rowan University
Head, Division of Infectious Diseases
Cooper University Health Care
Camden, New Jersey

John D. Baxter, MD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Clinical Care Options (CCO): South African patient’s perspective on living a full life with her HIV diagnosis, long-term ART, and HIV activism

person default Yvette Raphael Released: June 21, 2022

Clinical Care Options (CCO) patient audio: Yvette Raphael provides her perspectives and advice as an individual living with HIV

person default Yvette Raphael Released: June 21, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Gregory Huhn, MD, MPHTM Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: June 17, 2022 Expired: June 16, 2023

Audio from Dr Michelle Collins-Ogle and Clinical Care Options (CCO): Key HIV management considerations for pediatric patients

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: May 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings